Ejaculatory and Orgasmic Dysfunction Following Prostate Cancer Therapy: Clinical Management

Area of Science:

• Oncology
• Sexual Medicine
• Urology

Background:

• Erectile dysfunction is the primary focus of sexual health research post-prostate cancer treatment.
• Ejaculatory and orgasmic dysfunction are also significant, yet often overlooked, side effects.
• Orgasmic dysfunction encompasses premature ejaculation, anorgasmia, dysorgasmia, and climacturia.

Purpose of the Study:

• To review the prevalence of orgasmic dysfunction following prostate cancer treatment.
• To outline current management options for orgasmic dysfunction.
• To emphasize the importance of addressing orgasmic dysfunction in patient care.

Main Methods:

• A comprehensive literature search was conducted using Medline and Pubmed.
• Articles focusing on orgasmic dysfunction after prostate cancer treatment were identified and reviewed.

Main Results:

• Orgasmic dysfunction significantly impacts the quality of life for prostate cancer patients.
• Effective management strategies exist for various forms of orgasmic dysfunction.
• Current research and clinical practice often underemphasize orgasmic dysfunction.

Conclusions:

• Orgasmic dysfunction is a critical aspect of sexual health for prostate cancer survivors.
• Comprehensive sexual health management must include addressing orgasmic dysfunction.
• Further research and clinical attention are needed to improve patient outcomes.